Antimicrobial Drug Development Could Benefit From Smaller Clinical Trials, FDA Says

Studies of drugs for resistant pathogens could apply data from susceptible pathogens, CDER’s Powers tells Antimicrobial Resistance Interagency Task Force meeting. The agency plans to issue several antimicrobial-related guidances this summer.